ES2188612T3 - MULTIVESICULAR CYCLODEXTRINE LIPOSOMES TO ENCAPSULATE PHARMACOLOGICAL COMPOUNDS AND METHODS FOR USE. - Google Patents

MULTIVESICULAR CYCLODEXTRINE LIPOSOMES TO ENCAPSULATE PHARMACOLOGICAL COMPOUNDS AND METHODS FOR USE.

Info

Publication number
ES2188612T3
ES2188612T3 ES94916558T ES94916558T ES2188612T3 ES 2188612 T3 ES2188612 T3 ES 2188612T3 ES 94916558 T ES94916558 T ES 94916558T ES 94916558 T ES94916558 T ES 94916558T ES 2188612 T3 ES2188612 T3 ES 2188612T3
Authority
ES
Spain
Prior art keywords
cyclodextrine
liposomes
pharmacological compounds
methods
multivesicular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94916558T
Other languages
Spanish (es)
Inventor
Sinil Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pacira Pharmaceuticals Inc
Original Assignee
Skyepharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Skyepharma Inc filed Critical Skyepharma Inc
Application granted granted Critical
Publication of ES2188612T3 publication Critical patent/ES2188612T3/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/829—Liposomes, e.g. encapsulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

LOS LIPOSOMAS QUE TIENEN CICLODEXTRINA EN LA FASE ACUOSA ENCAPSULADA SON UTILES PARA LA ENCAPSULACION DE SUSTANCIAS BIOLOGICAMENTE ACTIVAS ESPECIALMENTE DE AQUELLAS QUE SON HIDROFILICAS. LA CICLODEXTRINA ENCAPSULADA FACILITA LA LIBERACION LENTA, CONTROLADA DE LOS COMPUESTOS FARMACOLOGICOS DE LOS LIPOSOMAS. LOS NUEVOS METODOS DE LA PRESENTE INVENCION PERMITEN EL TRATAMIENTO DE UNA VARIEDAD DE ESTADOS PATOFISIOLOGICOS MEDIANTE LA ADMINISTRACION DE LIPOSOMAS QUE CONTIENEN CICLODEXTRINA QUE ENCAPSULAN LOS COMPUESTOS FARMACOLOGICOS. EN LA PRESENTE INVENCION TAMBIEN SE PRESENTA UN NUEVO METODO PARA PROLONGAR LA VIDA MEDIA DE UN COMPUESTO FARMACOLOGICO EN UN ANIMAL.LIPOSOMES THAT HAVE CYCLODEXTRINE IN THE WATERPROOF PHASE ENCAPSULATED ARE USEFUL FOR THE ENCAPSULATION OF BIOLOGICALLY ACTIVE SUBSTANCES ESPECIALLY OF THOSE THAT ARE HYDROPHYLICAL. ENCAPSULATED CYCLODEXTRINE FACILITATES THE SLOW, CONTROLLED RELEASE OF THE PHARMACOLOGICAL COMPOUNDS OF LIPOSOMAS. THE NEW METHODS OF THE PRESENT INVENTION PERMIT THE TREATMENT OF A VARIETY OF PATHOPHYSIOLOGICAL STATES THROUGH THE ADMINISTRATION OF LIPOSOMES CONTAINING CYCLODEXTRINE CONCAPSULATING PHARMACOLOGICAL COMPOUNDS. IN THE PRESENT INVENTION A NEW METHOD IS ALSO PRESENTED TO EXTEND THE AVERAGE LIFE OF A PHARMACOLOGICAL COMPOSITE IN AN ANIMAL.

ES94916558T 1993-04-22 1994-04-22 MULTIVESICULAR CYCLODEXTRINE LIPOSOMES TO ENCAPSULATE PHARMACOLOGICAL COMPOUNDS AND METHODS FOR USE. Expired - Lifetime ES2188612T3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5113593A 1993-04-22 1993-04-22

Publications (1)

Publication Number Publication Date
ES2188612T3 true ES2188612T3 (en) 2003-07-01

Family

ID=21969560

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94916558T Expired - Lifetime ES2188612T3 (en) 1993-04-22 1994-04-22 MULTIVESICULAR CYCLODEXTRINE LIPOSOMES TO ENCAPSULATE PHARMACOLOGICAL COMPOUNDS AND METHODS FOR USE.

Country Status (11)

Country Link
US (1) US5759573A (en)
EP (1) EP0695169B1 (en)
JP (1) JP3545403B2 (en)
AT (1) ATE227979T1 (en)
AU (1) AU6818094A (en)
CA (1) CA2161225C (en)
DE (1) DE69431750T2 (en)
DK (1) DK0695169T3 (en)
ES (1) ES2188612T3 (en)
PT (1) PT695169E (en)
WO (1) WO1994023697A1 (en)

Families Citing this family (220)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995015746A1 (en) * 1993-12-10 1995-06-15 The School Of Pharmacy Liposome delivery systems
US5931809A (en) * 1995-07-14 1999-08-03 Depotech Corporation Epidural administration of therapeutic compounds with sustained rate of release
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
WO1998026080A1 (en) 1996-12-13 1998-06-18 Chiron Corporation Method for expression of heterologous proteins in yeast
US6511477B2 (en) * 1997-03-13 2003-01-28 Biocardia, Inc. Method of drug delivery to interstitial regions of the myocardium
US6443949B2 (en) * 1997-03-13 2002-09-03 Biocardia, Inc. Method of drug delivery to interstitial regions of the myocardium
ES2343767T3 (en) 1997-09-18 2010-08-09 Pacira Pharmaceuticals, Inc. LIPOSOMIC ANESTHETIC COMPOSITIONS OF SUSTAINED LIBERATION.
EP1900818A3 (en) 1997-11-06 2008-06-11 Novartis Vaccines and Diagnostics S.r.l. Neisserial antigens
JP4575592B2 (en) 1997-11-14 2010-11-04 パシラ ファーマシューティカルズ インコーポレーテッド Production of multivesicular liposomes
WO1999036544A2 (en) 1998-01-14 1999-07-22 Chiron S.P.A. Neisseria meningitidis antigens
EP2261347A3 (en) 1998-05-01 2012-01-11 Novartis Vaccines and Diagnostics, Inc. Neisseria meningitidis antigens and compositions
US7625859B1 (en) 2000-02-16 2009-12-01 Oregon Health & Science University HER-2 binding antagonists
US6740643B2 (en) * 1999-01-21 2004-05-25 Mirus Corporation Compositions and methods for drug delivery using amphiphile binding molecules
US20030008284A1 (en) 2000-06-15 2003-01-09 Giulia Kennedy Polynucleotides related to colon cancer
CZ20013103A3 (en) * 1999-03-02 2002-01-16 The Liposome Company, Inc. Encapsulating method of biologically active complexes into liposomes
CA2372235A1 (en) 1999-04-30 2000-11-09 Rino Rappuoli Conserved neisserial antigens
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
AUPQ259399A0 (en) 1999-09-01 1999-09-23 Lustre Investments Pte Ltd Therapeutic agents
EP1226253A2 (en) 1999-10-29 2002-07-31 Chiron S.P.A. Neisserial antigenic peptides
JP2003516731A (en) 1999-11-18 2003-05-20 カイロン コーポレイション Human FGF-21 gene and gene expression product
US20070219363A1 (en) * 1999-11-29 2007-09-20 Budker Vladimir G Chelating Compound for Drug Delivery
WO2001085093A2 (en) 1999-12-23 2001-11-15 Neurochem, Inc. Compounds and methods for modulating cerebral amyloid angiopathy
CA2871789C (en) 2000-01-17 2017-04-04 Novartis Vaccines And Diagnostics S.R.L. Outer membrane vesicle (omv) vaccine comprising n. meningitidis serogroup b outer membrane proteins
EP1261638A2 (en) 2000-03-08 2002-12-04 Chiron Corporation Human fgf-23 gene and gene expression products
EP1950297A2 (en) 2000-05-31 2008-07-30 Novartis Vaccines and Diagnostics, Inc. Compositions and methods for treating neoplastic disease using chemotherapy and radiation sensitizers
US7700359B2 (en) 2000-06-02 2010-04-20 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells
WO2003057926A1 (en) 2002-01-08 2003-07-17 Chiron Corporation Gene products differentially expressed in cancerous breast cells and their methods of use
ATE439372T1 (en) 2000-10-27 2009-08-15 Novartis Vaccines & Diagnostic NUCLEIC ACIDS AND PROTEINS OF GROUP A AND B STREPTOCOCICS
US20020160991A1 (en) * 2000-12-04 2002-10-31 Liming Shao Orally-bioavailable formulations of fentanyl and congeners thereof
EP2339035A1 (en) 2000-12-07 2011-06-29 Novartis Vaccines and Diagnostics, Inc. Endogenous retroviruses up-regulated in prostate cancer
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
WO2002081642A2 (en) 2001-04-06 2002-10-17 Georgetown University Gene brcc-3 and diagnostic and therapeutic uses thereof
AU2002305151A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene scc-112 and diagnostic and therapeutic uses thereof
AU2002303261A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene brcc2 and diagnostic and therapeutic uses thereof
BR0102252B1 (en) * 2001-04-10 2013-10-22 Angiotensin II AT1 Receptor Antagonist Controlled Release System, Pharmaceutical Composition and Use
EP1404713A4 (en) 2001-05-24 2004-09-22 Human Dna Technology Inc Novel keratinocyte growth factor-2 analogue in hair follicle
FR2827516B1 (en) * 2001-07-19 2003-09-19 Servier Lab PHARMACEUTICAL COMPOSITION FOR NASAL ADMINISTRATION OF ESTRADIOL AND NORETHISTERONE
BRPI0105509B8 (en) * 2001-11-05 2021-05-25 Univ Minas Gerais formulations of the angiotensin- (1-7) peptide using cyclodextrins, liposomes and the plga polymer
RU2316591C2 (en) 2001-11-09 2008-02-10 Джорджтаун Юниверсити New isoforms of vascular endothelial cell growth inhibitor
EP2168596B1 (en) 2001-12-12 2012-05-23 Novartis Vaccines and Diagnostics S.r.l. Immunisation against chlamydia trachomatis
AU2003218350A1 (en) 2002-03-21 2003-10-08 Sagres Discovery, Inc. Novel compositions and methods in cancer
US7138512B2 (en) 2002-04-10 2006-11-21 Georgetown University Gene SHINC-2 and diagnostic and therapeutic uses thereof
US7244565B2 (en) 2002-04-10 2007-07-17 Georgetown University Gene shinc-3 and diagnostic and therapeutic uses thereof
CA2489292A1 (en) 2002-06-13 2003-12-24 Chiron Corporation Vectors for expression of hml-2 polypeptides
AU2003257791A1 (en) * 2002-08-15 2004-03-29 Tong Liu Soild nano pharmaceutical formulation and preparation method thereof
UA80447C2 (en) 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
EP1556083B1 (en) 2002-10-08 2011-02-02 Rinat Neuroscience Corp. Methods for treating post-surgical pain by admisnistering an antibody against nerve growth factor and compositions containing the same
US7255860B2 (en) 2002-10-08 2007-08-14 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody
WO2004046177A2 (en) 2002-11-15 2004-06-03 Chiron Srl Unexpected surface proteins in neisseria meningitidis
EP2270048B1 (en) 2002-12-24 2015-11-11 Rinat Neuroscience Corp. Anti-NGF antibodies and methods using same
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
US7767387B2 (en) 2003-06-13 2010-08-03 Sagres Discovery, Inc. Therapeutic targets in cancer
JP2007524362A (en) 2003-02-14 2007-08-30 サイグレス ディスカバリー， インコーポレイテッド Therapeutic GPCR targets in cancer
US20040170982A1 (en) 2003-02-14 2004-09-02 Morris David W. Novel therapeutic targets in cancer
KR20050111598A (en) 2003-02-19 2005-11-25 리나트 뉴로사이언스 코퍼레이션 Methods for treating pain by administering a nerve growth factor antagonist and an nsaid and compositions containing the same
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
EP1667972B1 (en) 2003-09-10 2013-06-19 Brentwood Equities Ltd. Diastereomers of 4-aryloxy-3-hydroxypiperidines
AU2004308482A1 (en) 2003-12-23 2005-07-14 Rinat Neuroscience Corp. Agonist anti-trkC antibodies and methods using same
US8268324B2 (en) 2004-03-29 2012-09-18 Galpharma Co., Ltd. Modified galectin 9 proteins and use thereof
AU2005243247B2 (en) 2004-04-07 2012-03-01 Regents Of The University Of Minnesota Methods for treating bone cancer pain by administering a nerve growth factor antagonist
KR100896697B1 (en) 2004-04-09 2009-05-14 (주)아모레퍼시픽 Method for promoting percutaneous absorption of rhubarb extract by high pressure emulsification technology and external skin composition for whitening using the same
EP1789593B1 (en) 2004-07-09 2017-03-15 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Soluble forms of hendra virus g glycoprotein
US20060024677A1 (en) 2004-07-20 2006-02-02 Morris David W Novel therapeutic targets in cancer
GEP20115195B (en) 2004-07-30 2011-04-11 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide and use thereof
US7666442B2 (en) * 2004-08-31 2010-02-23 Tracie Martyn International, Llc Topical compositions comprising benfotiamine and pyridoxamine
US7939490B2 (en) 2004-12-13 2011-05-10 University Of Maryland, Baltimore TWEAK as a therapeutic target for treating central nervous system diseases associated with cerebral edema and cell death
JP2008530245A (en) 2005-02-18 2008-08-07 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド Antigens from uropathogenic strains
EP2083088A3 (en) 2005-04-07 2009-10-14 Novartis Vaccines and Diagnostics, Inc. Cancer-related genes
CA2604885A1 (en) 2005-04-07 2006-10-19 Guoying Yu Cacna1e in cancer diagnosis, detection and treatment
US20070014845A1 (en) * 2005-07-01 2007-01-18 Yuanpeng Zhang Liposomal delivery vehicle for hydrophobic drugs
WO2007014169A2 (en) 2005-07-22 2007-02-01 Y's Therapeutics Co, Ltd. Anti-cd26 antibodies and methods of use thereof
US20070055199A1 (en) 2005-08-10 2007-03-08 Gilbert Scott J Drug delivery device for buccal and aural applications and other areas of the body difficult to access
ES2433251T5 (en) 2005-11-14 2020-03-13 Teva Pharmaceuticals Int Gmbh Antagonistic antibodies directed against a peptide related to the calcitonin gene and procedures using them
PT1954292E (en) * 2005-11-28 2014-08-04 Verrow Pharmaceuticals Inc Compositions useful for reducing nephrotoxicity and methods of use thereof
US7658913B2 (en) 2005-11-28 2010-02-09 Verrow Pharmaceuticals, Inc. Compositions useful for reducing nephrotoxicity and methods of use thereof
KR100793824B1 (en) 2006-03-06 2008-01-11 (주)아모레퍼시픽 Polymer-Liposome Nanocomposites Carrying Soluble Soluble Bioactive Components Using Hydroxypropyl-Betacyclodextrin
CA2637707A1 (en) * 2006-02-02 2007-08-09 Rinat Neuroscience Corporation Methods for treating obesity by administering a trkb antagonist
CN101400367A (en) * 2006-02-02 2009-04-01 瑞纳神经科学公司 Methods for treating unwanted weight loss or eating disorders by administering a TRKB agonist
CN101516912B (en) 2006-06-07 2013-10-30 生物联合公司 Antibodies recognizing sugar-containing epitopes of CD-43 and CEA expressed on cancer cells and methods of use thereof
ATE522541T1 (en) 2006-06-09 2011-09-15 Novartis Ag BACTERIAL ADHESIN CONFORMERS
EP2586790A3 (en) 2006-08-16 2013-08-14 Novartis AG Immunogens from uropathogenic Escherichia coli
AP2009005028A0 (en) 2007-04-10 2009-12-31 Univ Tulane Soluble and membrane-anchored forms of lassa virussubunit proteins
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
WO2009077993A2 (en) 2007-12-17 2009-06-25 Pfizer Limited Treatment of interstitial cystitis
CN105732813A (en) 2007-12-18 2016-07-06 生物联合公司 Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same
US20090196917A1 (en) * 2008-02-01 2009-08-06 University Of Kentucky Research Foundation Liposomal Formulations of Hydrophobic Lactone Drugs in the Presence of Metal Ions
WO2009126306A2 (en) 2008-04-10 2009-10-15 Cell Signaling Technology, Inc. Compositions and methods for detecting egfr mutations in cancer
WO2009150623A1 (en) 2008-06-13 2009-12-17 Pfizer Inc Treatment of chronic prostatitis
US9492417B2 (en) 2008-08-21 2016-11-15 The Johns Hopkins University Methods and compositions for administration of 3-halopyruvate and related compounds for the treatment of cancer
TWI516501B (en) 2008-09-12 2016-01-11 禮納特神經系統科學公司 Pcsk9 antagonists
TW201032826A (en) * 2008-11-17 2010-09-16 Genentech Inc Method and formulation for reducing aggregation of a macromolecule under physiological conditions
WO2010086828A2 (en) 2009-02-02 2010-08-05 Rinat Neuroscience Corporation Agonist anti-trkb monoclonal antibodies
CN102438650A (en) 2009-03-06 2012-05-02 诺华有限公司 Chlamydia antigens
EP2415464B1 (en) 2009-03-30 2017-05-10 Eisai R&D Management Co., Ltd. Method for producing liposome composition
HRP20161157T1 (en) 2009-03-30 2016-11-18 Eisai R&D Management Co., Ltd. Liposome composition
US20100297127A1 (en) 2009-04-08 2010-11-25 Ghilardi Nico P Use of il-27 antagonists to treat lupus
NZ612315A (en) 2009-04-14 2014-10-31 Novartis Ag Compositions for immunising against staphylococcus aureus
PL2434886T3 (en) 2009-05-29 2020-05-18 Cydex Pharmaceuticals, Inc. Injectable melphalan compositions comprising a cyclodextrin derivative and methods of making and using the same
US11020363B2 (en) 2009-05-29 2021-06-01 Cydex Pharmaceuticals, Inc. Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same
WO2010146511A1 (en) 2009-06-17 2010-12-23 Pfizer Limited Treatment of overactive bladder
SI2464658T1 (en) 2009-07-16 2015-02-27 Novartis Ag Detoxified escherichia coli immunogens
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
AR080291A1 (en) 2010-02-24 2012-03-28 Rinat Neuroscience Corp ANTI-BODIES ANTAGONISTS ANTI RECEIVER OF IL-7 AND PROCEDURES
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
BR112012022917A2 (en) 2010-03-11 2017-01-10 Pfizer ph-dependent antigen binding antibodies
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
WO2011133931A1 (en) 2010-04-22 2011-10-27 Genentech, Inc. Use of il-27 antagonists for treating inflammatory bowel disease
US9993793B2 (en) 2010-04-28 2018-06-12 The Procter & Gamble Company Delivery particles
US9186642B2 (en) 2010-04-28 2015-11-17 The Procter & Gamble Company Delivery particle
US9770414B2 (en) * 2010-05-13 2017-09-26 Pacira Pharmaceuticals, Inc. Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (DMARD) and an anti-cancer agent
EP2598126A2 (en) 2010-07-30 2013-06-05 Saint Louis University Methods of treating pain
CN103260702B (en) * 2010-10-28 2018-07-27 帕西拉制药有限公司 Sustained-release formulations of nonsteroidal anti-inflammatory drugs
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
US10842849B2 (en) 2011-02-28 2020-11-24 The Schepens Eye Research Institute, Inc. Methods for promoting neuronal outgrowth by insulin-like growth factor binding protein-like 1 (IGFBPL-1) in glaucoma or leber's optic neuropathy
EP2694017B1 (en) 2011-04-07 2019-05-22 The Procter and Gamble Company Personal cleansing compositions with increased deposition of polyacrylate microcapsules
EP2694031B1 (en) 2011-04-07 2015-07-08 The Procter and Gamble Company Conditioner compositions with increased deposition of polyacrylate microcapsules
JP5869663B2 (en) 2011-04-07 2016-02-24 ザ プロクター アンド ギャンブルカンパニー Shampoo compositions with increased adhesion of polyacrylate microcapsules
US20130071375A1 (en) 2011-08-22 2013-03-21 Saint Louis University Compositions and methods for treating inflammation
WO2013028527A1 (en) 2011-08-23 2013-02-28 Indiana University Research And Technology Corporation Compositions and methods for treating cancer
US8871908B2 (en) 2011-11-11 2014-10-28 Rinat Neuroscience Corp. Antibodies specific for Trop-2 and their uses
JP2015502975A (en) 2011-12-22 2015-01-29 ライナット ニューロサイエンス コーポレイション Human growth hormone receptor antagonist antibodies and methods of use thereof
WO2013093693A1 (en) 2011-12-22 2013-06-27 Rinat Neuroscience Corp. Staphylococcus aureus specific antibodies and uses thereof
CN104427976B (en) 2012-05-10 2018-04-24 佩因拉佛姆有限公司 Hydrophobic depot formulations of active ingredient and preparation method thereof
US9421245B2 (en) 2012-06-25 2016-08-23 The Brigham And Women's Hospital, Inc. Targeted therapeutics
CA2877948C (en) 2012-07-02 2019-07-30 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Paramyxovirus and methods of use
JP2015524411A (en) * 2012-07-18 2015-08-24 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Liposome composition of epoxy ketone-based proteasome inhibitor
US8603470B1 (en) 2012-08-07 2013-12-10 National Cheng Kung University Use of IL-20 antagonists for treating liver diseases
KR20150082503A (en) 2012-11-09 2015-07-15 화이자 인코포레이티드 Platelet-derived growth factor b specific antibodies and compositions and uses thereof
HK1222331A1 (en) 2013-03-12 2017-06-30 通用医疗公司 Modified mullerian inhibiting substance (mis) proteins and uses thereof for the treatment of diseases
JP2016513682A (en) 2013-03-15 2016-05-16 ダイアックス コーポレーション Anti-plasma kallikrein antibody
WO2014181229A2 (en) 2013-05-07 2014-11-13 Rinat Neuroscience Corp. Anti-glucagon receptor antibodies and methods of use thereof
TWM473835U (en) * 2013-05-15 2014-03-11 吳旭昇 Micron burdock microlipid carrier structure
US20170172922A1 (en) * 2013-05-15 2017-06-22 Hsu-Shen WU Micron taiwanofungus camphoratus liposome structure
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
KR101809072B1 (en) 2013-08-02 2017-12-14 화이자 인코포레이티드 Anti-cxcr4 antibodies and antibody-drug conjugates
EP3068801A1 (en) 2013-11-13 2016-09-21 Pfizer Inc. Tumor necrosis factor-like ligand 1a specific antibodies and compositions and uses thereof
WO2015087187A1 (en) 2013-12-10 2015-06-18 Rinat Neuroscience Corp. Anti-sclerostin antibodies
US11135269B2 (en) 2013-12-11 2021-10-05 The General Hospital Corporation Use of mullerian inhibiting substance (MIS) proteins for contraception and ovarian reserve preservation
WO2015108932A1 (en) * 2014-01-14 2015-07-23 The Johns Hopkins University Liposome compositions encapsulating modified cyclodextrin complexes and uses thereof
WO2015109212A1 (en) 2014-01-17 2015-07-23 Pfizer Inc. Anti-il-2 antibodies and compositions and uses thereof
MX378344B (en) 2014-03-21 2025-03-10 Teva Pharmaceuticals Int Gmbh ANTAGONIST ANTIBODIES DIRECTED AGAINST CALCITONIN GENE-RELATED PEPTIDE AND METHODS USING THEM.
EP3122782A4 (en) 2014-03-27 2017-09-13 Dyax Corp. Compositions and methods for treatment of diabetic macular edema
US10308697B2 (en) 2014-04-30 2019-06-04 President And Fellows Of Harvard College Fusion proteins for treating cancer and related methods
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
TWI595006B (en) 2014-12-09 2017-08-11 禮納特神經系統科學公司 Anti-PD-1 antibodies and methods of using same
US11390687B2 (en) 2015-01-02 2022-07-19 Takeda Pharmaceutical Company Limited Bispecific antibodies against plasma kallikrein and Factor XII
US9758575B2 (en) 2015-04-06 2017-09-12 Yung Shin Pharmaceutical Industrial Co. Ltd. Antibodies which specifically bind to canine vascular endothelial growth factor and uses thereof
IL310723A (en) 2015-04-13 2024-04-01 Pfizer Therapeutic antibodies and their uses
TWM513697U (en) * 2015-06-26 2015-12-11 瑪神凱瑞生化科技股份有限公司 Carrier structure of imitation biological interstitial system
US10877045B2 (en) 2015-07-21 2020-12-29 Saint Louis University Compositions and methods for diagnosing and treating endometriosis-related infertility
JP7068160B2 (en) 2015-07-21 2022-05-16 武田薬品工業株式会社 Factor XIIa monoclonal antibody inhibitor
US11066481B2 (en) 2015-07-23 2021-07-20 The Regents Of The University Of California Antibodies to coagulation factor XIa and uses thereof
IL302353A (en) 2015-08-19 2023-06-01 Pfizer Tissue factor pathway inhibitor antibodies and uses thereof
PT3922645T (en) 2015-09-15 2025-05-29 Scholar Rock Inc Anti-pro/latent-myostatin antibodies and uses thereof
WO2017070561A1 (en) 2015-10-23 2017-04-27 Pfizer Inc. Anti-il-2 antibodies and compositions and uses thereof
WO2017075037A1 (en) 2015-10-27 2017-05-04 Scholar Rock, Inc. Primed growth factors and uses thereof
EP3370712B1 (en) 2015-11-06 2025-02-19 The Johns Hopkins University 3-bromopyruvate for treating liver fibrosis
CN106699889A (en) 2015-11-18 2017-05-24 礼进生物医药科技（上海）有限公司 PD-1 resisting antibody and treatment application thereof
KR20250057128A (en) 2015-12-30 2025-04-28 코디악 사이언시스 인코포레이티드 Antibodies and conjugates thereof
EP3397287B8 (en) 2015-12-30 2025-07-23 F. Hoffmann-La Roche AG Formulations with reduced degradation of polysorbate
CN109219618B (en) 2016-01-21 2022-08-09 辉瑞大药厂 Monospecific and bispecific antibodies against epidermal growth factor receptor variants III and CD3 and uses thereof
WO2017188350A1 (en) 2016-04-28 2017-11-02 エーザイ・アール・アンド・ディー・マネジメント株式会社 Method for inhibiting tumor growth
CN109983013A (en) 2016-11-18 2019-07-05 帕西拉制药有限公司 Meloxicam zinc complex microparticle multivesicular liposome preparation and preparation method thereof
KR20190124753A (en) 2017-03-03 2019-11-05 리나트 뉴로사이언스 코프. Anti-GITR Antibodies and Methods of Use thereof
US20200056190A1 (en) 2017-03-16 2020-02-20 Pfizer Inc. Tyrosine prototrophy
AU2018250695A1 (en) 2017-04-14 2019-11-07 Kodiak Sciences Inc. Complement factor D antagonist antibodies and conjugates thereof
EP3615570A4 (en) 2017-04-25 2021-02-24 LBL Biotechnology Inc. Use of il-20 antagonists for treating eye diseases
PE20242042A1 (en) 2017-06-02 2024-10-10 Pfizer FLT3-SPECIFIC ANTIBODIES AND THEIR USES
US11322226B2 (en) 2017-06-13 2022-05-03 Bostongene Corporation Systems and methods for generating, visualizing and classifying molecular functional profiles
WO2019016784A1 (en) 2017-07-21 2019-01-24 Universidade De Coimbra Anti-nucleolin antibody
EP3692370A2 (en) 2017-10-04 2020-08-12 OPKO Pharmaceuticals, LLC Articles and methods directed to personalized therapy of cancer
SG11202003652QA (en) 2017-10-27 2020-05-28 Univ New York Anti-galectin-9 antibodies and uses thereof
ES3062820T3 (en) * 2017-11-08 2026-04-14 L E A F Holdings Group Llc Platinum complexes and uses thereof
TWI878213B (en) 2018-02-01 2025-04-01 美商輝瑞大藥廠 Antibodies specific for cd70 and their uses
TW201936633A (en) 2018-02-01 2019-09-16 美商輝瑞大藥廠 Chimeric antigen receptors targeting CD70
WO2019166946A1 (en) 2018-02-28 2019-09-06 Pfizer Inc. Il-15 variants and uses thereof
US12071476B2 (en) 2018-03-02 2024-08-27 Kodiak Sciences Inc. IL-6 antibodies and fusion constructs and conjugates thereof
DK3797121T3 (en) 2018-05-23 2024-07-08 Pfizer Antibodies specific for CD3 and uses thereof
BR112020022595A2 (en) 2018-05-23 2021-02-09 Pfizer Inc. specific antibodies to gucy2c and uses thereof
KR20240119159A (en) * 2018-09-14 2024-08-06 파모사 바이오팜 인코포레이티드 Pharmaceutical composition for controlled release of weak acid drugs and uses thereof
CN112805301B (en) 2018-10-15 2023-07-21 安立玺荣生医(香港)有限公司 Antibodies to granulocyte-macrophage colony-stimulating factor and uses thereof
EP3898698B1 (en) 2018-12-21 2026-04-01 Multitude Therapeutics Co., Ltd. Chimeric antigen receptor specific to muc18
US11279774B2 (en) 2019-01-03 2022-03-22 Underdog Pharmaceuticals, Inc. Cyclodextrin dimers, compositions thereof, and uses thereof
CN114144190B (en) 2019-01-23 2025-08-08 纽约大学 Antibodies specific for the delta 1 chain of the T cell receptor
EP4567125A3 (en) 2019-07-03 2025-09-17 BostonGene Corporation Systems and methods for sample preparation, sample sequencing, and sequencing data bias correction and quality control
US12036204B2 (en) 2019-07-26 2024-07-16 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
US11083705B2 (en) 2019-07-26 2021-08-10 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
US20240050529A1 (en) 2019-10-07 2024-02-15 University Of Virginia Patent Foundation Modulating lymphatic vessels in neurological disease
AU2020364071A1 (en) 2019-10-10 2022-05-26 Kodiak Sciences Inc. Methods of treating an eye disorder
WO2021072244A1 (en) 2019-10-11 2021-04-15 Beth Israel Deaconess Medical Center, Inc. Anti-tn antibodies and uses thereof
EP4093426A1 (en) 2020-01-24 2022-11-30 University of Virginia Patent Foundation Modulating lymphatic vessels in neurological disease
WO2021205325A1 (en) 2020-04-08 2021-10-14 Pfizer Inc. Anti-gucy2c antibodies and uses thereof
US20230181750A1 (en) 2020-05-06 2023-06-15 Crispr Therapeutics Ag Mask peptides and masked anti-ptk7 antibodies comprising such
EP4165071A4 (en) 2020-06-15 2024-07-17 Academia Sinica HUMANIZED ACE2-FC FUSION PROTEIN FOR THE TREATMENT AND PREVENTION OF SARS-COV-2 INFECTION
CA3189590A1 (en) 2020-07-17 2022-01-20 Pfizer Inc. Therapeutic antibodies and their uses
US20230287455A1 (en) 2020-07-30 2023-09-14 Pfizer Inc. Cells Having Gene Duplications and Uses Thereof
CN116848146A (en) 2020-09-03 2023-10-03 I·S·Y·陈 Soluble alkaline phosphatase constructs and expression vectors comprising polynucleotides encoding soluble alkaline phosphatase constructs
US12486478B2 (en) 2020-10-16 2025-12-02 The Procter & Gamble Company Consumer products comprising delivery particles with high core:wall ratios
MX2023004231A (en) 2020-10-16 2023-04-21 Procter & Gamble CONSUMER PRODUCT COMPOSITIONS THAT COMPRISE A POPULATION OF ENCAPSULATES.
JP2023543578A (en) 2020-10-16 2023-10-17 ザ プロクター アンド ギャンブル カンパニー Consumer product compositions having at least two populations of inclusion bodies
CN112190498B (en) * 2020-10-31 2022-03-25 华南理工大学 Water-soluble theophylline and cyclodextrin inclusion compound and preparation method thereof
WO2022120256A2 (en) 2020-12-04 2022-06-09 Bostongene Corporation Hierarchical machine learning techniques for identifying molecular categories from expression data
US12151024B2 (en) 2021-01-22 2024-11-26 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US11357727B1 (en) 2021-01-22 2022-06-14 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US11278494B1 (en) 2021-01-22 2022-03-22 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US11033495B1 (en) 2021-01-22 2021-06-15 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US20220372580A1 (en) 2021-04-29 2022-11-24 Bostongene Corporation Machine learning techniques for estimating tumor cell expression in complex tumor tissue
EP4380969A1 (en) 2021-08-02 2024-06-12 Pfizer Inc. Improved expression vectors and uses thereof
GB2627096A (en) 2021-10-14 2024-08-14 Pacira Pharmaceuticals Inc Bupivacaine multivesicular liposome formulations and uses thereof
US20230245479A1 (en) 2022-01-31 2023-08-03 Bostongene Corporation Machine learning techniques for cytometry
KR20240139082A (en) 2022-02-02 2024-09-20 화이자 인코포레이티드 Cysteine prototrophy
US20240029884A1 (en) 2022-07-15 2024-01-25 Bostongene Corporation Techniques for detecting homologous recombination deficiency (hrd)
US20260120879A1 (en) 2023-10-31 2026-04-30 Bostongene Corporation Machine learning technique for identifying ici responders and non-responders
WO2025165590A1 (en) 2024-02-02 2025-08-07 Seven Bridges Genomics Inc. Techniques for improved tumor mutational burden (tmb) determination using a population-specific genomic reference
US12251468B1 (en) 2024-05-20 2025-03-18 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US12251472B1 (en) 2024-05-20 2025-03-18 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US12246092B1 (en) 2024-05-20 2025-03-11 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0261719A3 (en) * 1986-09-23 1990-10-10 Akzo N.V. Thermochemiluminescent cyclodextrin complexes
GB8704171D0 (en) * 1987-02-23 1987-04-01 Clayton Found Res Multivesicular liposomes
US5236907A (en) * 1988-10-01 1993-08-17 R-Tech Ueno Ltd. Ocular hypotensive agents
US5180716A (en) * 1990-08-01 1993-01-19 The Regents Of The University Of California Cyclodextrin complexes for neuraxial administration of drugs
GB9126209D0 (en) * 1991-12-10 1992-02-12 Orion Yhtymae Oy Drug formulations for parenteral use

Also Published As

Publication number Publication date
HK1013258A1 (en) 1999-08-20
WO1994023697A1 (en) 1994-10-27
DE69431750D1 (en) 2003-01-02
CA2161225C (en) 2003-07-01
CA2161225A1 (en) 1994-10-27
DK0695169T3 (en) 2003-03-17
AU6818094A (en) 1994-11-08
PT695169E (en) 2003-04-30
US5759573A (en) 1998-06-02
EP0695169B1 (en) 2002-11-20
EP0695169A4 (en) 1998-02-04
JPH08509230A (en) 1996-10-01
EP0695169A1 (en) 1996-02-07
ATE227979T1 (en) 2002-12-15
DE69431750T2 (en) 2003-04-03
JP3545403B2 (en) 2004-07-21

Similar Documents

Publication Publication Date Title
DE69434479D1 (en) Tramadol-containing drug with controlled release of active ingredient
ATE226815T1 (en) MANUFACTURING OF MEDICINAL PRODUCTS
AR007715A1 (en) STABLE AQUEOUS FORMULATION OF A PEPTIDE, A METHOD FOR PREPARING IT AND ITS USE FOR TREATMENT
DK618088D0 (en) PHARMACEUTICAL dosage form for controlled release of active substance
ES2157975T3 (en) PHARMACEUTICAL SOLUTIONS WITH IMPROVED SOLUBILITY.
ATE267007T1 (en) PHARMACEUTICAL TABLET SUITABLE FOR RELEASE OF ACTIVE INGREDIENTS IN CONSECUTIVE AND PREDETERMINABLE TIME PERIOD
NO20001410D0 (en) Sustained release liposomal anesthetics
AR018646A1 (en) WATER CARRIER SYSTEMS FOR INSOLUBLE WATER MATERIALS
ES2126536B1 (en) "PHARMACEUTICAL PREPARATION FOR INTRANASAL ADMINISTRATION AND PROCEDURE FOR ITS PRODUCTION".
ATE196248T1 (en) VESICLES WITH CONTROLLED RELEASE OF DRUGS
ES2148198T3 (en) PROCEDURE FOR CRUSHING PHARMACEUTICAL SUBSTANCES.
ES2104184T3 (en) COMPOSITIONS FOR THE TREATMENT OF INFLAMED TISSUES.
ES2077530A1 (en) Pharmaceutical products for curing tumorous diseases and process for preparing same
ES2171933T3 (en) ANDROSTENO DERIVATIVES.
NO904754D0 (en) Capsule for encapsulation of biologically active materials, method of preparation thereof, and use thereof.
DE69431750D1 (en) MULTIVESICULAR LIPOSOMES WITH ENCLOSED CYCLODEXTRIN AND PHARMACOLOGICALLY EFFECTIVE COMPOUNDS AND METHOD FOR THE USE THEREOF
EA199900734A1 (en) MICROCAPSULES CONTAINING CIS-PLATIN
KR960700061A (en) PHARMACEUTICAL COMPOSITION FOR TREATING NICOTINE DEPENDENCE
BG103738A (en) Pharmaceutical composition containing freeze-dry liposomes including hard-soluble active substance in water, and method for its preparation
PL311637A1 (en) Poured over preparations containing a polymer as well as glycerides and glycols
ES2124047T3 (en) PREPARED IN THE FORM OF CAPSULES FOR THE TREATMENT OF PLANTS.
ATE212543T1 (en) PHARMACEUTICAL COMPOSITION OF STABILIZED LIPOPHILIC MATRICES WITH CONTROLLED RELEASE OF ACTIVE INGREDIENTS
DE69410042D1 (en) Ester compound, active ingredient for controlling harmful parasites containing them as active substance, intermediate compound for the preparation of the ester compound, and method for producing the intermediate compound
KR890001518A (en) Opioid analgesic liposomes delivery-release system
CA2259194C (en) Transdermal compositions containing levosimendan